title: Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors.
abstract: Preoperative chemotherapy and endocrine therapy yielded low pathological complete remission (pCR) rates in patients with endocrine responsive breast cancer. Patients with large operable (cT2-T3, N0-2, M0), ER > or =10% breast cancer were treated in two consecutive studies with preoperative chemotherapy (Study I: six courses of either fluorouracil, leucovorin, vinorelbine (FLN), or vinorelbine, cisplatin, and continuous infusion of fluorouracil (ViFuP), at the discretion of the treating physician; Study II: capecitabine and oral vinorelbine (CAVINO)). Concurrent letrozole (in association with triptorelin if premenopause) was given. Sixty-five (58 evaluable) and 55 (all evaluable) patients were enrolled in the two studies. In Study I there were 43 objective responders (74%, 95% CI 63-85%), three of whom had pCR. Thirty-nine objective responses (91%) and all pCR were observed in patients with tumors expressing ER > or =50%. In Study II 34 patients (62%, 95% CI 49-75%) had an objective response. Endocrine therapy administered together with new intravenous, containing regimens should be explored in the preoperative treatment of endocrine responsive breast cancer.
authors.affiliation: Research Unit in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. rosalba.torrisi@ieo.it
authors.forename: Rosalba
authors.initials: R
authors.lastname: Torrisi
authors.forename: Silvia
authors.initials: S
authors.lastname: Dellapasqua
authors.forename: Raffaella
authors.initials: R
authors.lastname: Ghisini
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Viale
authors.forename: Paolo
authors.initials: P
authors.lastname: Veronesi
authors.forename: Alberto
authors.initials: A
authors.lastname: Luini
authors.forename: Mattia
authors.initials: M
authors.lastname: Intra
authors.forename: Giulia
authors.initials: G
authors.lastname: Peruzzotti
authors.forename: Andrea
authors.initials: A
authors.lastname: Rocca
authors.forename: Alessandra
authors.initials: A
authors.lastname: Balduzzi
authors.forename: Anna
authors.initials: A
authors.lastname: Cardillo
authors.forename: Aron
authors.initials: A
authors.lastname: Goldhirsch
authors.forename: Marco
authors.initials: M
authors.lastname: Colleoni
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000077289:Letrozole; D008408:Mastectomy; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077289:Letrozole